Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

BACKGROUND: Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy-induced nausea and vomiting (CINV) despite use of antiemetics. APF530 is a sustained-release subcutaneous (SC) formulation of granisetron for preventing CINV. APF530 phar...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Manag Res
Egile Nagusiak: Gabrail, Nashat, Yanagihara, Ronald, Spaczyński, Marek, Cooper, William, O’Boyle, Erin, Smith, Carrie, Boccia, Ralph
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2015
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4370683/
https://ncbi.nlm.nih.gov/pubmed/25834466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S72626
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak